A new survey from Define Ventures outlines how 15 of the top 20 pharmaceutical companies are embracing artificial intelligence, and where they’re implementing it. Carolyn Magill, venture partner at the VC firm, unpacks the results.
A new survey from Define Ventures outlines how 15 of the top 20 pharmaceutical companies are embracing artificial intelligence, and where they’re implementing it. Carolyn Magill, venture partner at the VC firm, unpacks the results.